Puma Biotechnology - Crunchbase Company Profile & Funding
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories - TheStreet
PumaBiotech (@pumabiotech) / Twitter
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Why Puma Biotechnology's Shares Jumped 20% on Monday | The Motley Fool
Puma Biotechnology
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Takeda offloads cancer drug to Puma
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Profit Outlook
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology | Evaluate
Puma Biotechnology, Inc. 2020 Current Report 8-K
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Articles with Puma Biotechnology
Puma Biotechnology
Exhibitor Puma Biotechnology 02-20 - Scripps CME Connection
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology, Inc.
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
